CBER: PDUFA IV Meeting Jesse L. Goodman, MD, MPH Director, Center for Biologics Evaluation and Research 11/14/05.

Slides:

Advertisements

Similar presentations

Rare Diseases and FDASIA

Advertisements

Overview Division of Viral Products Office of Vaccines Research and Review Laboratory of Methods Development Site Visit January 9, 2003.

Hepatitis A and Hepatitis A Vaccine Epidemiology and Prevention of Vaccine- Preventable Diseases National Immunization Program Centers for Disease Control.

ACIP Meeting Update November 4 th

Overview of the Division of Viral Products

Overview of the Division of Viral Products VRBPAC Presentation of the Site Visit Report for the Laboratories of Retrovirus Research, Immunoregulation,

Introduction to Regulation

An Overview of Mission-related Research Office of Blood Research and Review C.D. Atreya, Ph.D. Associate Director for Research OBRR, CBER BPAC, Dec

CBER Regulatory Laboratory Planning & Preparedness for SARS-related Biologics Products Kathryn M. Carbone MD Associate Director for Research, Acting, Center.

Center for Biologics Evaluation and Research Applying Regulatory Science to Advance Development of Innovative, Safe and Effective Biologic Products Carolyn.

I.1 ii.2 iii.3 iv.4 1+1=. i.1 ii.2 iii.3 iv.4 1+1=

Center for Biologics Evaluation and Research FDA Overview Site Visit Carolyn A. Wilson, Ph.D. Associate Director for Research.

I.1 ii.2 iii.3 iv.4 1+1=. i.1 ii.2 iii.3 iv.4 1+1=

CBER Managed Review Process Sheryl A. Kochman Deputy Director, DBA, OBRR, CBER September 15, 2009.

The FDA Landscape AdvaMed September 2008 Judith K. Meritz

Vaccines and Related Biological Products Advisory Committee Meeting

Serious adverse events following falsely high glucose measurements resulting from administration of an IGIV product containing maltose L. Ross Pierce,

TM 2011 Immunization Recommendations H. Cody Meissner, M.D. Professor of Pediatrics Tufts University School of Medicine Boston Floating Hospital for Children.

Critical Path Opportunities for Biologics Products Jesse L. Goodman, M.D. M.P.H. Director Kathryn M. Carbone, M.D. Associate Director for Research Center.

FDA, PDUFA AND MEDICAL INNOVATION Spring WHAT IS THE FOOD AND DRUG ADMINISTRATION (FDA)? The FDA is an agency within the U.S. Department of Health.

Fiscal Year 2011 CDC/ATSDR President’s Budget Request February 2, 2010.

Food and Drug Administration

1 Overview of the Laboratory of Hepatitis Viruses March 20, 2014 VRBPAC Discussion of the December 5, 2013 Site Visit for the Laboratory of Hepatitis Viruses.

Center for Biologics Evaluation and Research Carolyn A. Wilson, Ph.D. Associate Director for Research Applying Regulatory Science to Advance Development.

Update of The National Vaccine Plan Bruce G. Gellin, M.D., M.P.H., and Raymond A. Strikas, MD National Vaccine Program Office Department of Health and.

1 Overview of the Division of Viral Products February 28, 2014 VRBPAC Discussion of the August 28, 2013 Site Visit for the Laboratory of Respiratory Viral.

Meeting the Challenge of Pandemic Vaccine Preparedness: FDA Perspectives Jesse L. Goodman, MD, MPH Director, Center for Biologics Evaluation and Research.

Review of Site Visit Report Laboratory of Molecular Virology DETTD/OBRR/CBER March 18, 2005 Hira L. Nakhasi, Ph.D. Director, DETTD.

Thomas Clark, MD, MPH Centers for Disease Control and Prevention Immunization Program Managers Meeting November 16, 2010 Pertussis Epidemiology in the.

Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (Q-Pan H5N1 Vaccine) Manufactured by GlaxoSmithKline Vaccines and Related Biological Products Advisory.

National Vaccine Advisory Committee Report from the Chair Gus Birkhead, MD, MPH NVAC Chair February 3, 2010.

Enter Title of Presentation on Master Slide U.S. Department of Health and Human Services Office of the Assistant Secretary for Public Health Emergency.

FDA’s Critical Path Research Initiative & Intro to the CBER Research Program Kathryn M. Carbone, M.D. Associate Director for Research CBER/FDA.

FDA’s Role in Facilitating the Availability of Influenza Vaccine Norman W. Baylor, Ph.D. Director, Office of Vaccines Research and Review CBER/FDA.

Thomas Weiser, MD, MPH Medical Epidemiologist Portland Area Indian Health Service Northwest Portland Area Indian Health Board.

OFFICE OF VACCINES RESEARCH AND REVIEW Center for Biologics Evaluation and Research Michael J. Brennan, Ph.D. Associate Director for Research OVRR Site.

Update: Medical Device User Fee and Modernization Act of 2002 Blood Products Advisory Committee March 13, 2003 Mary Elizabeth Jacobs, Ph.D. Associate Director.

Research in the Office of Vaccines Research and Review: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation and Research.

Introduction to FDA’s Office of Vaccines Research and Review Norman W. Baylor, Ph.D. Director, Office of Vaccines Research and Review.

CBER Research: OBRR Office Site Visit Kathryn M. Carbone, MD Associate Director of Research CBER/FDA.

Research in the Office of Cellular, Tissue and Gene Therapies: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation.

Licensure of Apheresis Blood Products August 15, 2007 Lister Hill Auditorium, NIH Bethesda, MD.

BP10 Public Health Emergency Preparedness Grant Update Health & Medical Subpanel Pandemic Influenza Advisory Committee Meeting January 12, 2010 Mark J.

Center for Biologics Evaluation and Research, FDA Site Visit Introduction Kathryn M. Carbone, M.D. Associate Director for Research.

VACCINES AND RELATED BIOLOGICAL PRODUCTS ADVISORY COMMITTEE ALVAC-vCP1521 plus AIDSVAX B/E CRF01_AE (Clade E) -based HIV vaccines Phase 3 Trial in Thailand.

CBER Introduction to license application: Aventis Pasteur license application for Meningococcal (groups A, C, Y, and W135) Polysaccharide Diphtheria Toxoid.

OFFICE OF VACCINES RESEARCH AND REVIEW Center for Biologics Evaluation and Research Michael J. Brennan, Ph.D. Associate Director for Research OVRR Site.

Progress in adolescent vaccination coverage levels in the United States National Immunization Conference Washington, DC March 31, 2011 Shannon Stokley,

Mary Koslap-Petraco DNP, PNP-BC, CPNP Coordinator-Suffolk County Department of Health Services Hauppauge, NY.

1 Vaccines and Related Biological Products Advisory Committee Meeting FluBlok ® : Influenza Vaccine, Recombinant Hemagglutinin Applicant: Protein Sciences.

Ocean State Immunization Collaborative 2016 State - Supplied Vaccine Workshop May 17, 2016.

Date of download: 6/21/2016 From: Recommended Adult Immunization Schedule: United States, October 2007–September 2008(1) Ann Intern Med. 2007;147(10):

FDA DRUG APPROVAL FDA’s Lengthy Drug Approval Process in Twelve Steps Overview of the FDA Drug Approval Process Drug Developed June 13, 2016 | Emilia Varrone.

Director, Center for Biologics Evaluation and Research (CBER), FDA

Clinical Review Process for New Drug Development and Application

Expedited Drug Approval Programs

FDA Perspective on Cardiovascular Device Development

Vaccines and Related Biological Products Advisory Committee Meeting

Balancing Regulation and Innovation: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.

The Current PMA Requirements

Pertussis: New Vaccine, New Strategies

Fiscal Year 2011 CDC/ATSDR President’s Budget Request

Introduction of New Technology: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.

FDA-CDRH in the Next Decade A Vision for Change

Fiscal Year 2011 CDC/ATSDR President’s Budget Request

Dr.farahani MD-Mph Arak health center

What’s New in Adult Immunization

Strengthen Medicare Rx drug coverage Reform Medicare payment

Biocontainment Patient Care Unit--Consensus Standards

Presentation transcript:

CBER: PDUFA IV Meeting Jesse L. Goodman, MD, MPH Director, Center for Biologics Evaluation and Research 11/14/05

Vision for CBER INNOVATIVE TECHNOLOGY ADVANCING PUBLIC HEALTH Protect and improve public and individual health in the US and, where feasible, globally Facilitate the development, approval and access to safe and effective products and promising new technologies Strengthen CBER as a preeminent regulatory organization for biologics PDUFA has provided essential support in all these areas….

CBER User Fee Review Performance License Applications and Supplements % of First Actions Within Goal * for PDUFA I Cohort Fiscal Years * PDUFA I Performance Goals: FY93=No Goals, FY94=55%, FY95=70%, FY96=80%, FY97=90 (Indicated by Red Lines) Data for all years complete (L-250)RIMS 11/10/05

CBER User Fee Review Performance License Applications and Supplements % of First Actions Within Goal* for PDUFA II Cohort Fiscal Years PDUFA II Performance Goal: 90% (Indicated by Red Lines) (L-251)RIMS 11/10/05

CBER User Fee Review Performance License Applications and Supplements % of First Actions Within Goal* for PDUFA III Cohort Fiscal Years 2003 – 2007 PDUFA II Performance Goal: 90% (Indicated by Red Lines) Data as of 10/31/05 (L-251)RIMS 11/10/05

CBER PDUFA Meeting Management Performance % Actions Within Goal for PDUFA II Cohort Fiscal Years * PDUFA II Performance Goals: FY98=No Goals, FY99=70%, FY00=80%, FY01=90%, FY02=90 (Indicated by Red Lines) Data for all years complete RIMS 11/10/05

CBER PDUFA Meeting Management Performance % Actions Within Goal for PDUFA III Cohort Fiscal Years PDUFA III Performance Goal: 90% (Indicated by Red Lines) RIMS 11/10/05

Average Review Cycles for Priority and Standard CBER BLAs Receipt Cohort Fiscal Years Data as of September Average cycles in later years will increase as the 'slower' BLAs are approved. RIMS 11/10/05

Current CBER Offices PDUFA Meetings FY00-FY05 RIMS/

Selected Recent BLA Approvals Fluarix - Influenza Virus Vaccine (8/05) Accelerated approval Menactra - Meningococcal (Serogroups A, C, Y & W-135) Conjugate Vaccine (1/05) ProQuad - MMRV (9/05) Adacel - Tdap (adol. & adult) (6/05) Boostrix - Tdap (adolescent) (5/05)

Selected Recent BLA Approvals Immune Globulin IV products (8/03, Gammunex; 12/03, Flebogamma; 5/04, Octagam; 4/05 Gammagard Liquid) Rhophylac (Rho D Immune Globulin) 2/04 Vaccinia Immune Globulin IV Human ( 2/05) –Accelerated approval/Fast track designation Vaccinia Immune Globulin IV Human (5/05) –Accelerated approval/Fast track designation

Selected Recent BLA Efficacy Supplement Approvals Havrix – Hepatitis A Vaccine (10/05) VAQTA – Hepatitis A Vaccine (8/05) NovoSeven- Coagulation Factor VIIa (8/05)

PDUFA Summary PDUFA has helped to support an expert and efficient managed review process at CBER An important feature is intensive interactions with sponsors during product development The result is earlier access to safe, effective and innovative products, including lifesaving vaccines and blood products that are essential to our medical care and public health systems and to our nation's preparedness